Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y2S2
UPID:
CRYL1_HUMAN
Alternative names:
L-gulonate 3-dehydrogenase
Alternative UPACC:
Q9Y2S2; A0PJ43; B3KN92; Q0VDI1; Q7Z4Z9; Q9P0G7
Background:
Lambda-crystallin homolog, also known as L-gulonate 3-dehydrogenase, plays a pivotal role in metabolic processes. It showcases high L-gulonate 3-dehydrogenase activity, alongside lower dehydrogenase activity towards L-3-hydroxybutyrate (HBA) and L-threonate. This enzyme's unique catalytic capabilities underline its importance in the biochemical pathways it participates in.
Therapeutic significance:
Understanding the role of Lambda-crystallin homolog could open doors to potential therapeutic strategies. Its enzymatic functions suggest a significant, yet unexplored, potential in metabolic disorder treatments and beyond.